A
All patients with lower-risk chronic lymphocytic leukemia (CLL) should continue specialized follow-up
You're currently viewing OncGenius as a guest. To save your results, create an account or log in.
Advertisement
A study published by Brieghel et al in Blood Advances investigated 3-year clinical outcomes among patients with low-risk chronic lymphocytic leukemia (CLL) selected by clinical assessment to end specialized follow-up as compared with patients continuing with specialized follow-up.